Titan Pharmaceuticals (TTNP) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Do insiders & institutionals hold more shares of CASI or TTNP?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media refer more to CASI or TTNP?

In the previous week, CASI Pharmaceuticals and CASI Pharmaceuticals both had 1 articles in the media. CASI Pharmaceuticals' average media sentiment score of 1.89 equaled Titan Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Very Positive
Titan Pharmaceuticals	Very Positive

Is CASI or TTNP more profitable?

Titan Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -129.05%. Titan Pharmaceuticals' return on equity of -145.92% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-129.05%	-972.55%	-77.33%
Titan Pharmaceuticals	N/A	-145.92%	-129.20%

Which has more risk and volatility, CASI or TTNP?

CASI Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Which has higher earnings & valuation, CASI or TTNP?

Titan Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.56	-$39.26M	-$2.55	-0.51
Titan Pharmaceuticals	$180K	23.21	-$4.71M	-$4.59	-1.00

Do analysts recommend CASI or TTNP?

CASI Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 207.69%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Titan Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Titan Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CASI Pharmaceuticals beats Titan Pharmaceuticals on 8 of the 14 factors compared between the two stocks.